{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:56:28Z","timestamp":1781567788914,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2015,2,21]],"date-time":"2015-02-21T00:00:00Z","timestamp":1424476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s11046-015-9871-8","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T14:04:08Z","timestamp":1424441048000},"page":"359-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of Different In Vitro Tests to Detect Cryptococcus neoformans Not Susceptible to Amphotericin B"],"prefix":"10.1007","volume":"179","author":[{"given":"Susana","family":"C\u00f3rdoba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Vivot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Szusz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermina","family":"Isla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Davel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,21]]},"reference":[{"key":"9871_CR1","first-page":"113","volume":"36","author":"R Negroni","year":"2004","unstructured":"Negroni R, Helou SH, Lopez Daneri G, Robles AM, Arechavala A, Bianchi MH. Interrupci\u00f3n exitosa de la profilaxis secundaria antif\u00fangica en la criptococosis asociada al SIDA. Rev Argent Microbiol. 2004;36:113\u20137.","journal-title":"Rev Argent Microbiol"},{"key":"9871_CR2","first-page":"332","volume-title":"SIDA y enfermedades asociadas. Diagn\u00f3stico, cl\u00ednica y tratamiento","author":"R Negroni","year":"2008","unstructured":"Negroni R. Criptococosis. In: Benetucci J, editor. SIDA y enfermedades asociadas. Diagn\u00f3stico, cl\u00ednica y tratamiento. 3rd ed. Buenos Aires: FUNDAI; 2008. p. 332\u20136.","edition":"3"},{"key":"9871_CR3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","volume":"50","author":"JR Perfect","year":"2010","unstructured":"Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291\u2013322.","journal-title":"Clin Infect Dis"},{"key":"9871_CR4","unstructured":"Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. CLSI document M27-A3. 3rd ed. Wayne: Clinical and Laboratory Standards Institute; 2008. p. 19087\u20131898."},{"key":"9871_CR5","doi-asserted-by":"crossref","unstructured":"Arendrup MC, Cuenca-Estrella M, Lass-Fl\u00f6rl C, Hope W and the Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). Eucast Definitive Document EDef 7.2 Revision. Method for the determination of broth dilution minimum Inhibitory concentrations of antifungal agents for yeasts. www.eucast.org (2012).","DOI":"10.1111\/j.1469-0691.2012.03880.x"},{"key":"9871_CR6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/AAC.44.2.400-404.2000","volume":"44","author":"JL Rodr\u00edguez-Tudela","year":"2000","unstructured":"Rodr\u00edguez-Tudela JL, Mart\u00edn-Diez F, Cuenca-Estrella M, Rodero L, Carpintero Y, Gorgojo B. Influence of shaking of antifungal susceptibility testing of Cryptococcus neoformans: a comparison of NCCLS Standard M27-A medium, buffered yeast nitrogen base, and RPMI-2\u00a0% glucose. Antimicrob Agent Chemoter. 2000;44:400\u20134.","journal-title":"Antimicrob Agent Chemoter"},{"key":"9871_CR7","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/AAC.01631-10","volume":"55","author":"O Zaragoza","year":"2011","unstructured":"Zaragoza O, Mesa-Arango AC, G\u00f3mez-L\u00f3pez A, Bernal-Mart\u00ednez L, Rodr\u00edguez-Tudela JL, Cuenca-Estrella M. Process analysis of variables for standardization of antifungal susceptibility testing of nonfermentative yeasts. Antimicrob Agents Chemother. 2011;55:1563\u201370.","journal-title":"Antimicrob Agents Chemother"},{"key":"9871_CR8","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/AAC.00048-11","volume":"55","author":"N Govender","year":"2011","unstructured":"Govender N, Patel J, van Wyk M, Chiller T, Lockhart SR, GERMS-AS. Trends in antifungal drug susceptibility of cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002\u20132003 and 2007\u20132008. Antimicrob Agents Chemother. 2011;55:2606\u201311.","journal-title":"Antimicrob Agents Chemother"},{"key":"9871_CR9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.diagmicrobio.2011.07.007","volume":"71","author":"MA Pfaller","year":"2011","unstructured":"Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagn Microbiol Infect Dis. 2011;71:252\u20139.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"9871_CR10","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1128\/AAC.01115-12","volume":"56","author":"A Espinel-Ingroff","year":"2012","unstructured":"Espinel-Ingroff A, Aller AI, Canton E, et al. Cryptococcus neoformans\u2013Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole and voriconazole. Antimicrob Agents Chemother. 2012;56:5898\u2013906.","journal-title":"Antimicrob Agents Chemother"},{"key":"9871_CR11","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1128\/AAC.06252-11","volume":"56","author":"A Espinel-Ingroff","year":"2012","unstructured":"Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, et al. Cryptococcus neoformans\u2013Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother. 2012;56:3107\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"9871_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1413-8670(12)70301-X","volume":"16","author":"M Li","year":"2012","unstructured":"Li M, Liao Y, Chen M, Pan W, Weng L. Antifungal susceptibilities of Cryptococcus species complex isolates form AIDS and non-AIDS patients in southeast China. Braz Infect Dis. 2012;16:175\u20139.","journal-title":"Braz Infect Dis"},{"key":"9871_CR13","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1128\/AAC.01520-05","volume":"50","author":"E Dannaoui","year":"2006","unstructured":"Dannaoui E, Abdul M, Arpin M, et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother. 2006;50:2464\u201370.","journal-title":"Antimicrob Agents Chemother"},{"key":"9871_CR14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.riam.2009.02.001","volume":"26","author":"AI Arechavala","year":"2009","unstructured":"Arechavala AI, Ochiuzzi ME, Borgnia MD, Santiso GM. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy. Rev Iberoam Micol. 2009;26:194\u20137.","journal-title":"Rev Iberoam Micol"},{"key":"9871_CR15","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1128\/AAC.00034-11","volume":"55","author":"RA Larsen","year":"2011","unstructured":"Larsen RA, Bauer M, Pitisuttithum P, et al. Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome. Antimicrob Agents Chemother. 2011;55:5624\u201330.","journal-title":"Antimicrob Agents Chemother"},{"key":"9871_CR16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2334-12-361","volume":"12","author":"Ch Lee","year":"2012","unstructured":"Lee Ch, Chang TY, Liu JW, et al. Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis. BMC Infect Dis. 2012;12:361.","journal-title":"BMC Infect Dis"},{"key":"9871_CR17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1128\/AAC.39.4.906","volume":"39","author":"JH Rex","year":"1995","unstructured":"Rex JH, Chester R, Cooper JR, et al. Detection of amphotericin B-resistant candida isolates in a broth-based system. Antimicrob Agents Chemother. 1995;39:906\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"9871_CR18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/mmy.38.3.201.207","volume":"38","author":"L Rodero","year":"2000","unstructured":"Rodero L, C\u00f3rdoba S, Cahn P, et al. Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS. Med Mycol. 2000;38:201\u20137.","journal-title":"Med Mycol"},{"key":"9871_CR19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.diagmicrobio.2011.08.003","volume":"71","author":"S C\u00f3rdoba","year":"2011","unstructured":"C\u00f3rdoba S, Afeltra J, Vitale RG. Evaluation of the in vitro activity of amphotericin B by time kill curves methodology against Cryptococcus neoformans encapsulated and capsulate-deficient strains. Diagn Microbiol Infect Dis. 2011;71:260\u20132.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"9871_CR20","unstructured":"National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents: approved guideline. NCCLS document M26-A. Wayne, 1999."},{"key":"9871_CR21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1128\/CMR.17.2.268-280.2004","volume":"17","author":"MA Pfaller","year":"2004","unstructured":"Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev. 2004;17:268\u201380.","journal-title":"Clin Microbiol Rev"},{"key":"9871_CR22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00003088-200544020-00005","volume":"44","author":"JW Mouton","year":"2005","unstructured":"Mouton JW, Vinks AA. Pharmacokinetic\/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet. 2005;44:201\u201310.","journal-title":"Clin Pharmacokinet"},{"key":"9871_CR23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1128\/AAC.42.5.1207","volume":"42","author":"MA Klepser","year":"1997","unstructured":"Klepser MA, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother. 1997;42:1207\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"9871_CR24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1128\/AAC.42.5.1207","volume":"42","author":"ME Klepser","year":"1998","unstructured":"Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother. 1998;42:1207\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"9871_CR25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0732-8893(00)00173-5","volume":"38","author":"DS Burgess","year":"2000","unstructured":"Burgess DS, Hastings RW. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology. Diagn Microbiol Infect Dis. 2000;38:87\u201393.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"9871_CR26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1128\/AAC.46.2.578-581.2002","volume":"46","author":"EJ Ernst","year":"2002","unstructured":"Ernst EJ, Yodoi K, Roling EE, Klepser ME. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother. 2002;46:578\u201381.","journal-title":"Antimicrob Agents Chemother"},{"key":"9871_CR27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijantimicag.2013.10.024","volume":"43","author":"M Sandoval-Denis","year":"2014","unstructured":"Sandoval-Denis M, Pastor FJ, Capilla J, Sutton DA, Fothergill AW, Guarro J. In Vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungina in a murine infection by Candida lusitaniae. Int J Antimicrob Agents. 2014;43:161\u20134.","journal-title":"Int J Antimicrob Agents"},{"key":"9871_CR28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.diagmicrobio.2009.02.007","volume":"64","author":"MCSM Pappalardo","year":"2009","unstructured":"Pappalardo MCSM, Szeszs MW, Martins MA, et al. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology. Diagn Microbiol Infect Dis. 2009;64:146\u201351.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"9871_CR29","volume-title":"The yeast, a taxonomic study","author":"CP Kurtzman","year":"2011","unstructured":"Kurtzman CP, Fell JW. The yeast, a taxonomic study. 5th ed. Amsterdam: Elsevier; 2011.","edition":"5"},{"key":"9871_CR30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/JCM.16.1.22-29.1982","volume":"16","author":"R Ikeda","year":"1982","unstructured":"Ikeda R, Shinoda T, Fukazawa Y, Kaufman L. Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J Clin Microbiol. 1982;16:22\u20139.","journal-title":"J Clin Microbiol"},{"key":"9871_CR31","unstructured":"Neo-Sensitabs user\u2019s guide; A\/S Rosco Diagnostica, Taastrup, Denmark. 2007. http:\/\/www.rosco.uk ."},{"key":"9871_CR32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1128\/JCM.41.1.97-99.2003","volume":"41","author":"MJ Maxwell","year":"2003","unstructured":"Maxwell MJ, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans. J Clin Microbiol. 2003;41:97\u20139.","journal-title":"J Clin Microbiol"},{"key":"9871_CR33","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1128\/JCM.02316-09","volume":"48","author":"M Cuenca-Estrella","year":"2010","unstructured":"Cuenca-Estrella M, Gomez-Lopez A, Alastruey-Izquierdo A, et al. Comparison of the Vitek 2 antifungal susceptibility system with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution reference methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates. J Clin Microbiol. 2010;48:1782\u20136.","journal-title":"J Clin Microbiol"},{"key":"9871_CR34","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1099\/jmm.0.46789-0","volume":"55","author":"ALT Dias","year":"2006","unstructured":"Dias ALT, Matsumoto FE, Melhem MSC, et al. Comparative anlysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates. J Med Microbiol. 2006;55:1693\u20139.","journal-title":"J Med Microbiol"},{"key":"9871_CR35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11046-013-9710-8","volume":"176","author":"D Sow","year":"2013","unstructured":"Sow D, Clement Tine R, Sylla K, et al. Cryptococcal meningitis in Senegal: epidemiology, laboratory findings, therapeutic and outcome of cases diagnosed from 2004 to 2011. Mycopathologia. 2013;176:443\u20139.","journal-title":"Mycopathologia"},{"issue":"2","key":"9871_CR36","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/QAI.0000000000000147","volume":"66","author":"J Meda","year":"2014","unstructured":"Meda J, Kalluvya S, Downs JA, et al. Cryptococcal meningitis management in Tanzania with strict schedule of serial lumber punctures using intravenous tubing sets: an operational research study. J Acquir Immune Defic Syndr. 2014;66(2):e31\u20136. doi: 10.1097\/QAI.0000000000000147 .","journal-title":"J Acquir Immune Defic Syndr"},{"key":"9871_CR37","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3109\/13693781003733750","volume":"48","author":"ME Ochiuzzi","year":"2010","unstructured":"Ochiuzzi ME, Santiso GM, Arechavala AI. Correlation of Etest and neo-sensitabs diffusion assays on Mueller\u2013Hinton-methylene blue agar with broth microdilution reference method (CLSI-M27-A2) for testing susceptibilities of Cryptococcus neoformans to amphotericin B and fluconazole. Med Mycol. 2010;48:893\u20136.","journal-title":"Med Mycol"},{"key":"9871_CR38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1469-0691.2009.02997.x","volume":"16","author":"E Dannaoui","year":"2010","unstructured":"Dannaoui E, Paugam A, Develoux M, et al. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories. Clin Microbiol Infect. 2010;16:863\u20139.","journal-title":"Clin Microbiol Infect"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-015-9871-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11046-015-9871-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-015-9871-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T05:16:01Z","timestamp":1598764561000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11046-015-9871-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,21]]},"references-count":38,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["9871"],"URL":"https:\/\/doi.org\/10.1007\/s11046-015-9871-8","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,21]]}}}